Genentech Plans Avastin Glioblastoma sBLA In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech’s Phase III program is focused on line extensions, but earlier-stage pipeline includes multiple NMEs.
You may also be interested in...
Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Zabrowski’s number one concern? Filling the gap when products go off patent.
Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Zabrowski’s number one concern? Filling the gap when products go off patent.
Avastin Misses Overall-survival Endpoint In Lung Cancer
Analysts expect minimal damage to sales as a result of AVAiL data.